

Zonghui Hu

CONTACT INFORMATION	5601 Fisher Lane Rockville, MD 20852	240-669-5240 huzo@niaid.nih.gov
RESEARCH INTERESTS	Clinical trials, High dimensional data, Missing data and causal inference, Semiparametric models, Vaccine efficacy and design.	
EDUCATION	Texas A& M University , College Station, TX Ph.D., Statistics, 2004 M.S., Mathematics, 2000	
RESEARCH EXPERIENCE	Mathematical Statistician Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases National Institutes of Health Graduate Research Assistant Department of Statistics & Large Animal Clinic, Texas A& M University	2004 to present 2000 to 2004

REFEREED JOURNAL PUBLICATIONS

As a statistical methodologist, I have first author publications in *Journal of American Statistical Association*, *Biometrika*, *Journal of Royal Statistical Society Series C*, *Journal of Statistical Planning and Inference*, and *Statistics in Medicine*. As a biomedical researcher, I have published as key author in *New England Journal of Medicine*, *Proceedings of the National Academy of Science of the United States of America*, *Lancet*, *Blood*, and *AIDS* among others.

1. **Hu Z**, Proschan M. “Two-part test of vaccine effect.” **Statistics in Medicine**, 34: 1904-1911, 2015.
2. **Hu Z**, Follmann DA and Miura K. “Vaccine design via nonnegative lasso-based variable selection.” **Statistics in Medicine**, 34:1791-1798, 2015.
3. Zhang Z, Nie L, Soon G and **Hu Z**. “Robust Methods for Treatment Effect Calibration with Application to Non-Inferiority Trials.” **Biometrics**, under review, 2014.
4. Crank M, Gordon I, Yamshchikov G, Sitar S, **Hu Z**, Enama M, Holman L, Bailer R, Pearce M, Koup R, Mascola J, Nabel G, Tumpey T, Schwartz R, Graham B, and Ledgerwood J. “Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults (Rapid Development and Production of a Pandemic H1 DNA Vaccine).” **PLOS One**. DOI: 10.1371/journal.pone.0123969, 2015
5. **Hu Z**, Follmann DA and Wang N. “Effective balancing score for mean response estimation.” **Biometrika**, 101: 613–624, 2014.
6. **Hu Z**, Qin J, and Follmann DA. “Semiparametric mixture survival model with application to MRFIT study.” **Statistics and Its Interface**, 7: 19–26, 2014.
7. **Hu Z** and Follmann DA. “Acute-to-chronic ratio as a metric for HIV surveillance.” **Open Journal of Statistics**, 4: 111–117, 2014.

8. Ledgerwood JE, DeZure A, Stanley DA, Novik L, Enama ME, Berkowitz N, **Hu Z**, Joshi G, Ploquin A, Sitar S, Gordon IJ, Plummer SA, Holman LA, Hendel CS, Yamshchikov G, Roman F, Nicosia A, Colloca S, Cortese R, Bailer RT, Schwartz RM, Roederer M, Mascola JR, Koup RA, Sullivan NJ, Graham BS, and the VRC 207 Study Team. “Safety and Immunogenicity of Chimpanzee Adenovirus Vector Ebola Vaccine: Preliminary Report.” **New England Journal of Medicine**, DOI: 10.1056/NEJMoa1410863, 2014.
9. Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, **Hu Z**, Enama ME, Bailer RT, Koup RA, Schwartz RM, Akahata W, Nabel GJ, Mascola JR, Pierson TC, Graham BS, Ledgerwood JE, the VRC 311 Study Team. “Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.” **Lancet**, 384: 2046–2052, 2014.
10. Kibuuka H, Berkowitz NM, Millard M, Enama M, Tindikahwa A, Sekiziyivu A, Costner P, Sitar S, Glover D, **Hu Z**, Joshi G, Stanley D, Kunchai M, Bailer RT, Koup R, Nabel G, Mascola J, Sullivan N, Graham B, Michael N, Robb M. “Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.” **Lancet**, 385:1545–1554, 2014.
11. Sarwar UN, Costner P, Enama ME, Berkowitz N, **Hu Z**, Hendel CS, Sitar S, Plummer S, Mulangu S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Sullivan NJ, Graham BS, Ledgerwood JE, and the VRC 206 Study Team. “DNA vaccines encoding Ebolavirus and Marburgvirus wild type glycoproteins are safe and immunogenic in a phase I clinical trial.” **Journal of Infectious Diseases**, DOI: 10.1093/infdis/jiu511, 2014.
12. Swaminathan S, **Hu Z**, Rupert A, Chen Q, Stevens R, Rehm C, Metcalfe J, Baseler M, Lane C and Imamichi T. “Plasma Interleukin-27 (IL-27) levels are not modulated in patients with chronic HIV-1 infection.” **PLOS ONE**, 9(6): e98989, 2014.
13. Saout C, Hasley R, Imamichi H, Tcheung L, **Hu Z**, Luckey M, Park J, Durum S, Smith M, Rupert A, Sneller M, Lane C and Catalfamo M. “Chronic exposure to type-I INF under lymphopenic conditions alters CD4 T cell homeostasis.” **PLOS Pathogens**, 10(3): e1003976, 2014.
14. Ledgerwood J, Zephir K, **Hu Z**, Wei CJ, Chang LJ, Enama M, Hendel S, Sitar S, Bailer R, Koup R, Mascola J, Nabel G, Graham B and the VRC 310 Study Team. “Boost interval matters: a randomized phase I study to identify the minimum interval to observe the H5 DNA influenza vaccine priming effect.” **Journal of Infectious Disease**, 208(3):418–422, 2013.
15. Miura K, Herrera R, Diouf A, Zhou H, Mu J, **Hu Z**, MacDonald N, Reiter K, Nguyen V, Shimp R, Singh K, Narum D, Long C and Miller L. “Overcoming allelic-specificity by immunization with 5-allelic forms of Plasmodium falciparum Apical Membrane Antigen 1.” **Infection and Immunity**, 81(5):1491–1501, 2013.
16. Hasley R, Hong C, Li W, Friesen T, Wilhelm C, Nakamura Y, Kim G, Park J, Hixon J, Durum S, **Hu Z**, Sneller M, Imamichi T, Oguariri R, Lane CH and Catalfamo M. “HIV immune activation drives increased expression of Eomesodermin in memory CD8 T cells in association with transcriptional downregulation of CD127.” **AIDS**, 27(12):1867–1877, 2013.

17. Hurley A, Smith M, Karpova T, Hasley RB, Belkina N, Shaw S, Balenga N, Druey KM, Nickel E, Packard B, Imamichi H, **Hu Z**, Follmann DA, McNally J, Higgins J, Sneller M, Lane CH and Catalfamo M. “Enhanced effector function of CD8 T cells from healthy controls and HIV infected patients occurs through thrombin activation of the Protease-activated receptor-1.” **The Journal of Infectious Disease**, 207(4): 638-650, 2013.
18. **Hu Z**, Follmann DA and Qin J “Semiparametric double balancing score estimation for incomplete data with ignorable missingness.” **Journal of American Statistical Association**, 107: 247–257, 2012.
19. Ledgerwood JE, **Hu Z**, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS and the VRC 304 and VRC 305 Study Teams. “H5 DNA Influenza Vaccination is Immunogenic by Intradermal and Intramuscular Routes in Humans.” **Clinical and Vaccine Immunology** (<http://cvi.asm.org/content/early/2012/08/30/05663-11.full.pdf>).
20. Enama ME, **Hu Z**, Gordon I, Costner P, Ledgerwood JE, Grady C. “Comparison of standard and simplified consent forms in investigational influenza vaccine clinical trials.” **Contemporary Clinical Trials**, 33: 895–902, 2012.
21. Osinusi A, Naggie S, Poonia S, Trippler M, **Hu Z**, Schlaak JF, Fishbein D, Masur H, Polis MA, Kottitil S. “ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in HIV/HCV co-infected patients.” **Journal of Medical Virology**, 84: 1106-1114, 2012.
22. Sneller MC, **Hu Z** and Langford CA. “A Randomized Controlled Trial of Rituximab Following Failure of Antiviral Therapy for Hepatitis C-Associated Cryoglobulinemic.” **Arthritis & Rheumatism**, 64: 835–842, 2012.
23. **Hu Z**, Follmann DA, and Qin J “Dimension reduced kernel estimation for distribution function with incomplete data.” **Journal of Statistical Planning and Inference**, 141: 3084–3093, 2011.
24. Ledgerwood JE, Wei CJ, **Hu Z**, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Yassine H, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS1 and the VRC 306 Study Team (2011). “DNA priming improves influenza vaccine immunogenicity in humans.” **Lancet**, 11:912–924, 2011.
25. Hodge JN, Srinivasula S, **Hu Z**, Read SW, Porter BO, Mican J, Paik C, Di Mascio M and Sereti I. “Decreases in IL-7 levels during ART suggest a primary mechanism of receptor-mediated clearance with IL-7 levels normalizing despite persistent CD4 lymphopenia.” **Blood**, 118:3244–3253, 2011.
26. Matthews GV, Manzini P, **Hu Z**, Khabo P, Maja P, Mutchaba G, Sangweni P, Metcalf J, Pool N, Orsega S, Emery S on behalf of the PHIDISA II study team. “Impact of 3TC on HIV and HBV related outcomes in HIV/HBV individuals in a randomized clinical trial of antiretroviral therapy in South Africa.” **AIDS**, 14:1727–1735, 2011.
27. Dlamini J, **Hu Z**, Morris L, Somaroo H, Ledwaba J, Maldarelli F, Highbarger H, Sangweni P, Follman D, Dewar R, Pau A, and the Phidisa Study Group. “Genotypic Resistance at Viral Rebound among Patients Who Received Lopinavir/ritonavir- or Efavirenz-Based First Antiretroviral Therapy in South Africa.” **Journal of Acquired Immune Deficiency Syndrome**, 58:304–308, 2011.
28. Dlamini J, **Hu Z**, Somaroo H, Highbarger H, Sangweni P, Follman D, Dewar R, Pau A. “Lack of effect from a previous single dose of Nevirapine on virologic

- and immunologic responses after 6 months of antiretroviral regimens containing efavirenz or lopinavir-ritonavir.” **Pharmacotherapy**, 31: 158–163, 2011.
29. **Hu Z**, Follmann DA, and Qin J “Semiparametric dimension reduction estimation for mean response with missingness.” **Biometrika**, 97: 301–319, 2010.
 30. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, **Hu Z**, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS and the VRC 205 Study Team. “A Replication Defective Recombinant Ad5 Vaccine Expressing Ebola Virus GP Is Safe and Immunogenic in Healthy Adults.” **Vaccine**, 29: 304-313, 2010.
 31. Brittain E and **Hu Z** “Non-inferiority trial design and analysis with an ordered three-level categorical endpoint. ” **Journal of Biopharmaceutical Statistics**, 19: 685–699, 2009.
 32. Komarow H, **Hu Z**, Brittain E, Uzzaman A, Gaskins D, Metcalfe DD. “Serum tryptase levels in atopic and non-atopic children.” **Journal of Allergy and Clinical Immunology**, 124: 845–848, 2009.
 33. Hill VL, Simpson VZ, Higgins J, **Hu Z**, Stevens RA, Metcalf JA and Baseler M. “Evaluation of the Performance of the Sysmex XT-2000i Hematology Analyzer with Whole Bloods Stored at Room Temperature.” **Lab Medicine**, 40: 709–718, 2009.
 34. **Hu Z**, Qin J, and Follmann DA “Semiparametric two-sample change-point model.” **Journal of Royal Statistical Society Series C**, 57: 589–607, 2008.
 35. **Hu Z** and Wang, N. “Semiparametric mixed-effects model with latent covariate in Colon carcinogenesis study.” **Statistics and Its Interface**, 1: 75–86, 2008.
 36. **Hu Z**, Qin J, Follmann DA, and Dewar, R. “Nonparametric likelihood approach for assessing the accordance between two measurements and its application to viral load determination with limit of detection.” **Statistics in Medicine**, 27: 4489–4501, 2008.
 37. Catalfamo M, Di Mascio M, **Hu Z**, Srinivasula S, Thaker V, Adelsberger J, Rupert A, Baseler M, Tagaya Y, Roby G, Rehm C, Follmann D and Lane C. “HIV infection associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells.” **Proceedings of the National Academy of Sciences of the United States of America**, 105: 19851–19856, 2008.
 38. Suzman DL, McLaughlin M, **Hu Z**, Kleiner DE, Wood B, Vailati M, Lempicki RA, Mican JM, Suffredini A, Masur F, Polis MA and Kottlil S. “Identification of novel markers for liver fibrosis in HIV/HCV co-infected individuals using genomics-based approach.” **AIDS**, 22: 1433–1439, 2008.
 39. **Hu Z** and Follmann DA “Statistical methods for active extension trials.” **Statistics in Medicine**, 26:2433–2448, 2007.
 40. Highbarger HC, **Hu Z**, Kottlil S, Metcalf JA, Polis MA, Vasudevachari MB, Lane CH and Dewar R. “Comparison of the Abbott 7000 and Bayer 340 systems for measurement of Hepatitis C viral load.” **Journal of Clinical Microbiology**, 45: 2808–2812, 2007.

41. Pau AK, McLaughlin M, **Hu Z**, Polis MA, Kotttilil S. “Predictors for Hematopoietic Growth Factors Use in HIV/HCV Co-Infected Patients Treated with Peginterferon alfa 2b and Ribavirin.” **AIDS Patient Care and STDs**, 9: 612–619, 2006.
42. Wu L, Kotttilil S, Lempicki R, Yang J, McLaughlin M, **Hu Z**, Koratich C, Rehm C, Masur H, Kleiner DE, Polis MA. “Hepatic histologic response (HR) to combination therapy among HCV/HIV coinfecting individuals: Interferon-induces HR independent of Sustained Virologic Response (SVR).” **AIDS Research and Human Retroviruses**, 22:1091–1098, 2006.
43. **Hu Z**, Wang N and Carroll RJ. “Profile-Kernel versus backfitting in the partially linear models for longitudinal/clustered data.” **Biometrika**, 91:251–262, 2004.
44. Cohen N, **Hu Z**, Stanley, SD and Wang N. “ Comparison of serum and urinary concentration of clenbuterol with and without concomitant administration of furosemide in horses.” **Veterinary Therapy**, 3: 316–325, 2002.
45. Nelson P and **Hu Z**. “ Consistency of the Synchronized Traffic Flow of Kerner with a Diffusively Corrected Lighthill?Whitham Model.” **Proceedings of Traffic and Transportation Studies 2000**, 594–601.

PAPERS IN
PREPARATION

1. “Semiparametric pseudoscore estimation with missingness in regressor”.
2. “ Causal inference based on case-control type observational data”.

INVITED
PRESENTATIONS

- Office of Biostatistics Research, National Heart, Lung and Blood Institute, Bethesda, MD November 2014
- The 3rd IMS Asia Pacific Rim Meeting, Taipei, Taiwan June 2014
- Department of Biostatistics, Johns Hopkins University, Baltimore, MD April 2014
- Department of Biostatistics, Georgetown University, DC, November 2013
- Department of Statistics, University of Michigan, Ann Arbor, MI September 2011
- International Chinese Statistical Association, New York, NY June 2011
- Department of Statistics, George Mason University, VA December 2009
- Department of Mathematical Sciences, Portland State University, Portland, OR April 2008
- Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD June 2004
- International Chinese Statistical Association, San Diego, CA June 2004
- CDRH, Food and Drug Administration, Rockville, MD September 2003

SERVICE

- International Chinese Statistical Association (ICSA) membership committee 2011-2013
- Organizer of topic contributed session “Estimation and Inference with incomplete data”, JSM, Montreal, Canada August 2013
- Referee for *Journal of American Statistical Association*, *Biometrics*, *Statistica Sinica*, *Statistics in Medicine*, *Journal of Statistical Planning and Inference*, *Statistics and Its Interface*, *Statistical Computation and Graphics*, *Canadian Journal of Statistics*, *Communications in Statistics-Theory and Methods*, *Scandinavian Journal of Statistics*, *TEST*, *Annals of Internal Medicine*.